## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.2% below STRENGTH zone (3.0-6.0%); PEG 1.71 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($70.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Curodont Drill-Free Caries Treatment to Be Distributed by Henry Schein Across U.S. Dental Market**
- Source: Orthodontic Products | 20251202T220656 | Bullish | Relevance: 100%
- Henry Schein Inc. announced an expanded agreement with vVARDIS to become the exclusive U.S. distributor of the Curodont Repair Fluoride Plus product across all dental market segments, effective January 1, 2026. This expansion builds on a previous agreement and extends Henry Schein's distribution rights to general dentistry, orthodontics, and pediatric dentistry practices nationwide. Curodont is a drill-free caries treatment for early-stage cavities, and this partnership aims to make it more accessible to the entire U.S. dental community given its success in reaching over 10% of U.S. dental offices.

**2. Henry Schein Inc. stock underperforms Tuesday when compared to competitors**
- Source: MarketWatch | 20251202T172300 | Somewhat-Bearish | Relevance: 100%
- Henry Schein Inc. (HSIC) stock fell 1.97% to $71.67 on Tuesday, underperforming the broader market which saw the S&P 500 Index (SPX) rise 0.25% and the Dow Jones Industrial Average (DJIA) gain 0.39%. This marks the fourth consecutive day of losses for the company's stock.

**3. HSIC Stock Benefits From Expanded Partnership With vVARDIS**
- Source: TradingView | 20251202T152143 | Bullish | Relevance: 100%
- Henry Schein, Inc. (HSIC) has expanded its partnership with vVARDIS, gaining exclusive U.S. distribution rights for the Curodont Repair Fluoride Plus product starting January 1, 2026. This move is expected to bolster HSIC's Dental business and maintain positive stock momentum, building on previous strategic collaborations. The drill-free Curodont product addresses early-stage cavities, tapping into a significant market opportunity and aligning with the company's commitment to advancing oral health.

**4. Hsbc Holdings PLC Raises Stake in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251204T140924 | Somewhat-Bullish | Relevance: 100%
- Hsbc Holdings PLC increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 15.9% during the second quarter, bringing its total to 155,065 shares valued at $11.33 million. The article notes that institutional investors now own 96.62% of the company, and Henry Schein recently surpassed quarterly earnings estimates with strong revenue and guidance for FY2025. Analysts currently maintain a "Hold" rating on the stock with an average price target of $76.17.

**5. How Investors May Respond To Henry Schein (HSIC) Gaining Exclusive U.S. Rights To Drill-Free Cavity Treatment**
- Source: Simply Wall Street | 20251204T062725 | Somewhat-Bullish | Relevance: 100%
- Henry Schein (HSIC) has secured exclusive U.S. distribution rights for vVARDIS's drill-free Curodont Repair Fluoride Plus product, expanding its role in preventive oral healthcare. This move, alongside advancements like VideaHealthâ€™s Detect AI, supports Henry Schein's strategy to shift towards higher-margin specialties and digital solutions. Despite these growth initiatives, investors should remain aware of ongoing price competition risks in core dental supplies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-05 | JP Morgan | $78 | $76 | +3% |
| 2025-11-05 | Barrington Rese | $79 | $78 | +1% |
| 2025-11-05 | Morgan Stanley | $58 | $55 | +5% |
| 2025-11-05 | Wells Fargo | $76 | $70 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-05 | JP Morgan | main | Overweight |
| 2025-11-05 | Barrington Rese | main | Outperform |
| 2025-11-05 | Morgan Stanley | main | Underweight |
| 2025-11-05 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +5%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.71 elevated, pricing in significant growth expectations. Analyst sentiment positive (5 raises, avg +5%). Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.71 |
| Forward P/E | 13.9 |
| Current P/E | 14.9 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.4% to -2.2% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.24% (CS: 29) | Weak |
| RSI_14 | 58.3 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.079x | Above |
| vs SMA200 | 1.059x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $73.34
- **Stop Loss:** $70.00 (4.6% risk)
- **Target:** $76.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 149
- **Position Value:** $10,927.66
- **Portfolio %:** 10.93%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*